Kathleen Dorritie
Program: Cancer Therapeutics
Summary
Dr. Dorritie specializes in hematologic malignancies, with a focus on multiple myeloma and lymphoma. She played a key role in the development of the chimeric antigen receptor (CAR) T-cell and bispecific antibody programs at UPMC. She serves as lead or co-investigator on several clinical trials in these areas. She currently serves on the ECOG Lymphoma Committee and SWOG Myeloma Committee.
